How many insider declarations has Sands Capital Life Sciences Pulse Fund II, L.P. filed?

Sands Capital Life Sciences Pulse Fund II, L.P. has filed 1 public insider declaration with SEC (Form 4).

What is Sands Capital Life Sciences Pulse Fund II, L.P.'s role?

Sands Capital Life Sciences Pulse Fund II, L.P.'s reported role is not specified by the regulator across the filings.

Which companies does Sands Capital Life Sciences Pulse Fund II, L.P. report trades for?

Sands Capital Life Sciences Pulse Fund II, L.P. reports trades for Inhibikase Therapeutics, Inc..

What is Sands Capital Life Sciences Pulse Fund II, L.P.'s declared buy vs sell volume?

Across the available history, declared buys total 2.6M€ and disposals 0.

← Executives ★ Sign in to follow

SC

Sands Capital Life Sciences Pulse Fund II, L.P.

·SEC (Form 4)

Inhibikase Therapeutics, Inc.

0

Total declarations

0

Company

€3m

▲ Purchases (1 ops.)

—

▼ Sales (0 ops.)

Insider track record

Other

Disclosed buys

1

Disclosed sells

0

T+90 hit rate

100%

T+90 mean return

+14.6%

Across 1 buy signal with a settled T+90 return. Return basis: close on the day after publication.

Signal history

No signal scores available.

Discover the complete record of transactions filed by Sands Capital Life Sciences Pulse Fund II, L.P.. Officer active across 1 company, notably Inhibikase Therapeutics, Inc.. Aggregated, 1 disclosures have been published. Split: 1 buy · 0 sell. Total volume traded: €2.6m. Activity tracked since 21 November 2025. The latest transaction was disclosed on 21 November 2025 (Acquisition). Regulator: SEC (Form 4). All data is accessible without signup.

Companies and markets linked to Sands Capital Life Sciences Pulse Fund II, L.P.

Open company profiles for insider transactions, fundamentals and analyst consensus when available.

Inhibikase Therapeutics, Inc. (US)

Declarations1 total

▲

Sands Capital Life Sciences Pulse Fund II, L.P.

Executives21 Nov 2025Inhibikase Therapeutics, Inc.

$3M14SEC ↗

2,068,965 shares@ US$1.45100.0% of flowCommon StockSEC:0001875620-25-000025:0

Canonical exit: 19 Feb 2026 (T+90)

1 of 1 declaration

InsidersTradesSigma

← Executives ★ Sign in to follow

SC

Sands Capital Life Sciences Pulse Fund II, L.P.

·SEC (Form 4)

Inhibikase Therapeutics, Inc.

0

Total declarations

0

Company

€3m

▲ Purchases (1 ops.)

—

▼ Sales (0 ops.)

Insider track record

Other

Disclosed buys

1

Disclosed sells

0

T+90 hit rate

100%

T+90 mean return

+14.6%

Across 1 buy signal with a settled T+90 return. Return basis: close on the day after publication.

Signal history

No signal scores available.

Discover the complete record of transactions filed by Sands Capital Life Sciences Pulse Fund II, L.P.. Officer active across 1 company, notably Inhibikase Therapeutics, Inc.. Aggregated, 1 disclosures have been published. Split: 1 buy · 0 sell. Total volume traded: €2.6m. Activity tracked since 21 November 2025. The latest transaction was disclosed on 21 November 2025 (Acquisition). Regulator: SEC (Form 4). All data is accessible without signup.